#USA #San Diego #Kenai Therapeutics #RNDP-001 #Allen Waldrop

Kenai Therapeutics Strengthens Board with Allen Waldrop

In a pivotal move to bolster its growth and clinical development, Kenai Therapeutics, a pioneering clinical-stage biotechnology firm focused on neurological conditions, has welcomed Allen Waldrop to its Board of Directors. This appointment comes at a crucial period as the company embarks on the next steps for its lead therapeutic candidate, RNDP-001.

Expertise to Drive Innovation

Allen Waldrop, who previously held significant roles in finance, brings a wealth of experience in institutional investment strategies. As the current Deputy Chief Investment Officer for Private Markets at the Alaska Permanent Fund Corporation, Waldrop oversees an impressive portfolio valued at approximately $87 billion. His responsibilities span across Private Equity, Private Credit, Infrastructure, and Real Estate investments, making him an invaluable asset to Kenai as the company navigates the complex landscape of clinical trials and product development.

Kenai's CEO, Nick Manusos, expressed his enthusiasm over Waldrop's appointment, emphasizing the critical role his expertise will play in advancing RNDP-001, a novel approach aimed at ameliorating the symptoms of Parkinson's disease. With Waldrop's guidance in capital planning and strategic oversight, Kenai aims to effectively propel its research forward and enhance its overall portfolio of neurological therapies.

RNDP-001: A Promising Solution for Parkinson's

RNDP-001 represents a breakthrough in therapeutic strategies, functioning as an allogeneic neuron replacement cell therapy designed specifically to replace dopamine-producing neurons lost in Parkinson's disease. Currently undergoing evaluation in a Phase 1 REPLACE™ clinical trial, this treatment is in the delicate stage of assessing both safety and tolerability among adult patients suffering from moderate to severe forms of the condition.

Initial outcomes from the trial, which includes brain imaging to assess cell survival and integration, are anticipated to emerge in late 2026. Furthermore, RNDP-001 has received Fast Track designation from the U.S. FDA, signaling a critical recognition of the urgent need for innovative treatments in this area of healthcare. This clinical trial is notably supported by funding from the California Institute for Regenerative Medicine (CIRM), which underscores the broad interest and investment in regenerative medicine pathways.

A Background Rich in Financial Strategy

Waldrop's journey in finance commenced at KPMG, followed by pivotal roles within various investment and consulting firms, where he honed his skills in portfolio management and financial analytics. He carries a Bachelor of Science degree in Accounting from San Diego State University and holds credentials as a CFA charterholder and an inactive Certified Public Accountant. His extensive background equips him to provide Kenai with the oversight necessary for navigating complex financial dynamics in drug development.

About Kenai Therapeutics

Founded in 2022 and headquartered in San Diego, California, Kenai Therapeutics stands at the forefront of biotech innovations targeting neurological disorders. By utilizing a proprietary iPSC platform, the company is dedicated to developing accessible, allogeneic therapies, like RNDP-001, aimed at making tangible differences in patients' lives affected by neurological diseases. Kenai's strategic partnership with FUJIFILM Cellular Dynamics, Inc. allows for scalable production capabilities, ensuring that breakthroughs are not only innovative but also feasible in terms of mass production.

Incorporating Waldrop into their governance structure marks a significant step for Kenai Therapeutics as they align their operational capabilities with strategic financial leadership. The biotechnology company is poised to make substantial advancements in neurodegenerative treatment options as it continues its mission to transform care for patients in need.

For more details about the company's projects and research initiatives, visit Kenai Therapeutics and keep updated on their progress via their LinkedIn and Bluesky profiles.